image credit- shuttershock.com
South Korea based Bukwang Pharmaceuticals recently announced that the US Food and Drug Administration (FDA) has approved a phase 2 trial of JM-010.
JM-010 is a new drug candidate developed by Danish Bioventure Contera Pharma, a subsidiary of Bukwang Pharmaceutical.
The approved trial will be conducted in about 30 institutions in the United States to evaluate the safety and effectiveness of JM-010 in 190 patients with side effects of dyskinesia caused by Parkinson's disease. Dyskinesia is uncontrolled, involuntary movement that may occur with long-term levodopa use and longer time with Parkinson's.
As JM-010 is entering the global clinical stage, it is already well-proven and plans to enter the KOSDAQ through the technology listing of foreign companies.
